Hum. Reprod. Advance Access originally published online on December 16, 2005
Human Reproduction 2006 21(3):632-639; doi:10.1093/humrep/dei386
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial*
1 C.B.Lambalk, Department of Reproductive Medicine, Vrije Universiteit Medical Centre, Amsterdam, the Netherlands, 2 A Leader, Civic Parkdale Clinic, Ottawa, Ontario, Canada, 3 F Olivennes, CHU Antoine Beclere, Clamart, France, 4 MR Fluker, Genesis Fertility Center, Vancouver, Canada, 5 A Nyboe Andersen, Juliane Marie Centret Fertilitetsklinikken, Kopenhagen, Denmark, 6 J Ingerslev, Fertilitetsklinikken, Skejby Sygehus, Arhus, Denmark, 7 Y Khalaf, Assisted conception Unit, Guy’s Hospital, London, UK, 8 Avril C, Clinique Saint Antoine, Bois Guillaume, France, 9 J Belaisch-Allart, Hopital Jean Rostand, Sevres, France, 10 R Roulier, Institut Medical de la Reproduction, Marseille, France and 11 B Mannaerts, Organon, Oss, The Netherlands
12 To whom correspondence should be addressed at: Department of Reproductive Medicine, Vrije Universiteit Medical Centre (Vumc), de Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands. E-mail: cb.lambalk{at}vumc.nl
BACKGROUND: This study was designed to assess whether the use of ganirelix in women undergoing stimulated IUI could prevent the occurrence of premature LH rises and luteinization (LH + progesterone rises). METHODS: Women of infertile couples, diagnosed with unexplained or male factor infertility, were randomized to receive either ganirelix (n = 103) or placebo (n = 100) in a double-blind design. All women were treated with an individualized, low-dose rFSH regimen started on day 2–3 of cycle. Ganirelix (0.25 mg/day) was started if one or more follicles 
14 mm were visualized. Ovulation was triggered by HCG injection when at least one follicle 18 mm was observed and a single IUI was performed 34–42 h later. The primary efficacy outcome was the incidence of premature LH rises (± progesterone rise). RESULTS: In the ganirelix group, four subjects had a premature LH rise (value 10 IU/l), one LH rise prior to the start of ganirelix and three LH rises during ganirelix treatment, whereas in the placebo group 28 subjects had a premature LH rise, six subjects prior to the start of placebo and 22 subjects during placebo treatment. The incidence of LH rises was significantly lower in ganirelix cycles compared to placebo cycles (3.9 versus 28.0%; P = 0.003 for ITT analysis). When excluding subjects with an LH value 10 IU/l before the start of ganirelix/placebo the incidence of LH rises was also significantly lower in ganirelix cycles compared to placebo cycles (2.9 versus 23.4%; P = 0.003 for ITT analysis). Premature luteinization (LH rise with concomitant progesterone rise 1 ng/ml) was observed in one subject in the ganirelix group and in 17 subjects in the placebo group of which three subjects had a premature spontaneous ovulation. Ongoing pregnancy rates per attempt were 12.6 and 12.0% for the ganirelix and placebo groups respectively. CONCLUSIONS: Treatment with ganirelix effectively prevents premature LH rises, luteinization in subjects undergoing stimulated IUI. Low-dose rFSH regimen combined with a GnRH antagonist may be an alternative treatment option for subjects with previous proven luteinization or in subjects who would otherwise require insemination when staff are not working.
Key words: male factor infertility/mild stimulation/premature LH rises/recombinant FSH/unexplained infertility
* Dr Olivennes and Dr Leader presented data from the study at ESHRE, Berlin, 2004 and ASRM, Philadelphia, 2004.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. la Cour Freiesleben, K. Lossl, J. Bogstad, H.E. Bredkjaer, B. Toft, M. Rosendahl, A. Loft, S. Bangsboll, A. Pinborg, and A. Nyboe Andersen Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study Hum. Reprod., October 1, 2009; 24(10): 2523 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The ESHRE Capri Workshop Group Intrauterine insemination Hum. Reprod. Update, May 1, 2009; 15(3): 265 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Devroey, M. Aboulghar, J. Garcia-Velasco, G. Griesinger, P. Humaidan, E. Kolibianakis, W. Ledger, C. Tomas, and B. C.J.M. Fauser Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment Hum. Reprod., April 1, 2009; 24(4): 764 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Bedaiwy, N. A. Mousa, N. Esfandiari, R. Forman, and R. F. Casper Follicular Phase Dynamics with Combined Aromatase Inhibitor and Follicle Stimulating Hormone Treatment J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 825 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.G. Crosignani, E. Somigliana, and on behalf of the Intrauterine Insemination (IUI) S Effect of GnRH antagonists in FSH mildly stimulated intrauterine insemination cycles: a multicentre randomized trial Hum. Reprod., February 1, 2007; 22(2): 500 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Allegra, A. Marino, F. Coffaro, P. Scaglione, F. Sammartano, G. Rizza, and A. Volpes GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial Hum. Reprod., January 1, 2007; 22(1): 101 - 108. [Abstract] [Full Text] [PDF]
|
|